The website Healio has profiled a study led by Jennifer Goralski, MD, on triple therapy in young children with cystic fibrosis. The study, published in The American Journal of Respiratory and Critical Care Medicine, is titled “Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2 Through 5 Years with Cystic Fibrosis and at Least One F508del Allele” and can be accessed via PubMed here. The Healio article, “Triple therapy shows safety, tolerability for young children with cystic fibrosis,” can be read here.